Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA

Kristen M. Pluchino1, Dominic Esposito2, Janna K. Moen1, Matthew D. Hall1, James P. Madigan1, Suneet Shukla1, Lauren V. Procter2, Vanessa E. Wall2, Thomas D. Schneider3, Ian Pringle4, Suresh V. Ambudkar1, Deborah R. Gill4, Steven C. Hyde4, Michael M. Gottesman1*

1 Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States of America, 2 Protein Expression Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States of America, 3 Gene Regulation and Chromosome Biology Laboratory, National Cancer Institute, Molecular Information Theory Group, Frederick, MD, United States of America, 4 Gene Medicine Research Group, NDCLS, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

* mgottesman@nih.gov

Abstract

The efflux transporter P-glycoprotein (P-gp) is an important mediator of various pharmacokinetic parameters, being expressed at numerous physiological barriers and also in multidrug-resistant cancer cells. Molecular cloning of homologous cDNAs is an important tool for the characterization of functional differences in P-gp between species. However, plasmids containing mouse mdr1a cDNA display significant genetic instability during cloning in bacteria, indicating that mdr1a cDNA may be somehow toxic to bacteria, allowing only clones containing mutations that abrogate this toxicity to survive transformation. We demonstrate here the presence of a cryptic promoter in mouse mdr1a cDNA that causes mouse P-gp expression in bacteria. This expression may account for the observed toxicity of mdr1a DNA to bacteria. Sigma 70 binding site analysis and GFP reporter plasmids were used to identify sequences in the first 321 bps of mdr1a cDNA capable of initiating bacterial protein expression. An mdr1a M107L cDNA containing a single residue mutation at the proposed translational start site was shown to allow sub-cloning of mdr1a in E. coli while retaining transport properties similar to wild-type P-gp. This mutant mdr1a cDNA may prove useful for efficient cloning of mdr1a in E. coli.

Introduction

Since its identification nearly 35 years ago, the ATP-Binding Cassette (ABC) transporter P-glycoprotein (P-gp, ABCB1, MDR1) has been extensively studied and characterized. P-gp plays a vital role in the transport of molecules across cell membranes, recognizing a diverse range of substrates and using the energy from ATP hydrolysis to efflux molecules from cells, irrespective of the prevailing concentration gradient [1]. Physiologically, P-gp functions in both excretory and protective capacities by regulating concentration gradients of xenobiotics across biological
membranes, being expressed in the liver, kidneys, lungs, and gastrointestinal tract and acting to efflux exogenous compounds and their metabolites into the bile, urine, mucus, and feces, respectively [2]. P-gp is also expressed at various physiological barriers, in endothelial cells of capillaries of the blood-brain barrier (BBB), the blood-cerebrospinal fluid barrier (CSF), and the blood-testis and blood-placental barriers [3,4]. P-gp recognizes a diverse range of substrates, including various therapeutically relevant natural product compounds, steroids, antiepileptic drugs, antibiotics, HIV protease inhibitors, immunosuppressive drugs, cardiac glycosides, and analgesics [5]. Thus, a consequence of these numerous roles is that P-gp can affect pharmacokinetic parameters of drug absorption, distribution, metabolism, excretion and toxicity [6]. Additionally, numerous anti-cancer drugs used in the clinic have been identified as substrates of P-gp, and overexpression of P-gp has been shown to correlate with overall poor chemotherapy response and prognosis and often prevents the successful treatment of cancer [5,7].

Full-length cDNAs of P-gp from various species are important for the functional characterization of human P-gp homologs. For example, in vivo models can be helpful to determine the biodistribution and metabolism of drugs in a pre-clinical setting, allowing drugs with undesirable pharmacokinetic parameters to be identified during drug development. However, these models are limited, as P-gp homologs from various species have shown both subtle and profound functional differences [8–13]. Additionally, several crystal structures of P-gp homologs, including those of mouse and C. elegans P-gp, have been recently reported, and a comprehensive understanding of functional differences between mouse and human P-gp homologs is required to understand both the impact and limitations of structural data [14–18]. P-gp cDNA from the species of interest are required to study functional differences between P-gp homologs in expression systems.

While P-gp cDNA is of critical importance for various experimental systems, propagation of mouse P-gp (mdr1a) cDNA in bacteria has proven difficult. Researchers in this laboratory and others have frequently observed the appearance of mutated mdr1a cDNA upon transformation into bacteria. This suggests mdr1a cDNA may be somehow toxic to E. coli, allowing only sub-clones with randomly occurring mutations in mdr1a cDNA that mitigate this selective pressure to survive transformation. Exogenous genetic material, such as cDNAs from eukaryotic organisms, may harbor sequences that are able to act as bacterial promoters and self-initiate their expression upon introduction into bacteria. Sequences from non-prokaryotic genomes that are able to induce transcription in a bacterial host are termed ‘cryptic promoters’ [19,20]. When present, cryptic promoters self-induce protein expression. Therefore, unintentional expression of plasmid cDNA may occur even in the absence of prokaryotic promoters in the plasmid vector. Deleterious effects on host bacteria as a result of protein expression resulting from a cryptic bacterial promoter have been previously reported with both mammalian and viral cDNAs [19,20]. Additionally, expression of eukaryotic membrane proteins (such as P-gp) in bacteria often leads to toxicity or cell death, as membrane-spanning domains can compromise the integrity of the cell membrane [21–23].

We hypothesized that the presence of a cryptic bacterial promoter in mdr1a cDNA, which results in the unintentional expression of P-gp, may account for observed difficulties in mdr1a propagation in bacteria. This study characterizes the genetic instability of mdr1a through transformation of mdr1a cDNA into E. coli and subsequent plasmid screening and sequencing to identify acquired mutations. Sigma 70 binding site analysis was used to identify the sequences of mdr1a cDNA capable of mdr1a transcription and translation in bacteria. Based on this analysis, GFP reporter constructs composed of N-terminal sequences of mdr1a fused to GFP were used to characterize the presence of a cryptic promoter. We discovered that sequences in the first 321 bps of mdr1a were able to express GFP. Lastly, an mdr1a cDNA
M107L mutant that showed increased genetic stability was generated and functionally characterized.

Materials and Methods

Materials

All chemicals were sourced from Sigma Aldrich, St. Lois, MO unless otherwise stated.

Bacterial and mammalian cell culture

Chemically competent One Shot Top10 E. coli cells were used for all sub-cloning and were cultured and transformed according to the manufacturer’s protocol (Life Technologies, Carlsbad, CA). Transformed E. coli cells were cultured with 100 μg/mL ampicillin, 50 μg/mL kanamycin, or 100 μg/mL zeocin depending on the antibiotic resistance gene contained in the plasmid backbone. The mammalian human embryonic kidney (HEK) 293 cell line was grown at 37°C in 5% CO₂ and cultured in DMEM, supplemented with 10% fetal bovine serum, 5 mM L-glutamine, 50 units/mL penicillin, and 50 μg/mL streptomycin. Additionally, the human and mouse P-gp-expressing cell lines KB-8-5-11 and C3M were cultured in 100 ng/mL and 1 μg/mL colchicine, respectively, to maintain P-gp expression [24,25].

Topo-cloning of PCR products

Cloning of agarose gel purified blunt-end PCR products was carried out using the Zero Blunt TOPO PCR Cloning Kit (Life Technologies, Carlsbad, CA, USA) into the supplied pCR-Blunt TOPO cloning plasmid according to the manufacturer’s protocols.

Plasmids for GFP analysis

Plasmids were constructed using Multisite Gateway recombinational cloning (Life Technologies, Carlsbad, CA) using the manufacturer’s instructions. In each case, two separate Entry clones were recombined into the final Destination vector, pDest-302. This vector is a Gateway modified version of pUC19 and contains no prokaryotic promoter regions upstream of the cloning site. GFP plasmids contained the complete sequence of enhanced GFP (from pIRE-S2-eGFP) preceded by either a strong E. coli ribosome binding site and ATG start codon derived from pET43a (p300-GFP, p-GFP, λpR-GFP) or an in-frame tobacco etch virus protease cleavage site lacking an ATG start codon (p321-GFP, p321-M107L-GFP). The upstream mdr1a-containing Entry clones had regions of mouse mdr1a amplified from cDNA by PCR, and were fully sequence verified to ensure no mutations were introduced during amplification. The M107L mutation was introduced into one of these clones during amplification using a modified primer. The p-GFP stuffer region consisted of a portion of the E. coli chloramphenicol acetyl transferase gene which lacked prokaryotic promoter activity, had no ATG codons, and had stop codons present in all reading frames to ensure no transcriptional or translational activity. The λpR-GFP region contained a 203 bp region of the bacteriophage lambda early DNA which encodes the highly active phage pR promoter (Genbank Refseq NC_001416).

Plasmids for HEK-293 transfection

Full length human P-gp was amplified by PCR from cDNA and used to construct a Gateway Entry clone that was fully sequence verified. Mouse M107L P-gp was generated by overlap extension PCR from cDNA constructs and used to construct a Gateway Entry clone, which was also fully sequence verified. Both Entry clones were sub-cloned into pDest-780, a Gateway
modified version of pcDNA3.2 (Life Technologies, Carlsbad, CA), which allows expression of
the gene of interest with the strong CMV promoter.

**Lipofectamine transfection**

Lipofectamine transfections were performed using Lipofectamine 2000 Reagent according to
the manufacturer’s protocol (Life Technologies, Carlsbad, CA). Briefly, 5×10^5 HEK-293 cells
were transfected with 2 μg of plasmid DNA. HEK-293 cells were incubated for 24 hours, after
which media was replaced with media containing 100 nM paclitaxel and incubated for an addi-
tional 48 hours before harvesting.

**Purification of plasmid DNA**

For small-scale plasmid purification, 2–5 mL of culture was purified using the Wizard Plus SV
Miniprep DNA Purification system (Promega, Madison, WI) according to the manufacturer’s
protocol. For large-scale plasmid purification, 200–500 mL of culture was purified using the
HiSpeed Plasmid Maxi Kit (Qiagen, Limburg, Netherlands) according to the manufacturer’s
protocol.

**Sequencing and sequence analysis of DNA**

Sequencing was carried out using Big Dye Terminator sequencing kits (Life Technologies,
Carlsbad, CA). Analysis of sequencing chromatograms was carried out using MacVector align-
ment software (MacVector, Cary, NC). Sequencing chromatograms of wild-type mdr1a and
MDR1 were aligned to reference sequences from Genbank identifications NM_011076.2
(mdr1a) and NM_000927.4 (MDR1).

**Fluorescence spectroscopy**

Fluorescence spectroscopy was used to determine levels of GFP fluorescence in bacteria trans-
formed with GFP plasmids. One Shot Top10 Chemically Competent E. coli cells were trans-
formed with GFP plasmids, and transformants were plated on LB agar containing the
appropriate antibiotic selective agent. Colonies were selected for growth in 5 mL of LB media
for 12 hours. Cultures were centrifuged and LB media was removed. Cell pellets were resus-
pended in PBS and transferred to a 96-well, black walled plate for fluorescence analysis. Fluoro-
rescence intensity was measured by the FLUOstar Omega fluorometer (BMG Labtech,
Ortenberg, Germany).

**Confocal microscopy**

Transformed E. coli to be analyzed for GFP fluorescence by confocal microscopy were trans-
ferred to chambered coverslips. Cells were imaged with a Zeiss LSM 710 NLO confocal micro-
scope and images were processed by Zen 2012 software (Zeiss, Jena, Germany).

**Western blotting**

Samples were prepared by combining the desired amount of protein with 1x SDS sample buffer
and loaded into each well of a Bis-Tris SDS-PAGE gel and electrophoresed at 150 V in 1x
MOPS running buffer (Life Technologies, Carlsbad, CA). Protein was transferred to a PVDF
membrane using the iBlot Dry Blotting System (Life Technologies, Carlsbad, CA). Membranes
were blocked in 10% non-fat milk for at least 1 hour. After blocking, membranes were incu-
bated with either the C219 (Fujirebio Diagnostics, Malvern, PA) or GAPDH primary antibody
for 1 hour. Membranes were washed and incubated with the anti-mouse IgG HRP-linked
secondary antibody for an additional hour before addition of chemiluminescent horseradish peroxidase (HRP) antibody detection reagent and exposure to chemiluminescence film. All antibodies in this study were used at a 1:10,000 dilution.

**ATPase assay**

ATPase assays were carried out using membranes prepared from baculovirus-infected High-five insect cells as previously described [8,26]. Membrane vesicles (10 μg of protein) were incubated with varying concentrations of the drug to be tested in the presence and absence of 0.3 mM sodium orthovanadate in ATPase 2x assay buffer (100 mM MES-Tris buffer (pH 6.8), 100 mM KCl, 10 mM sodium azide, 2 mM EGTA, 2 mM ouabain, 20 mM MgCl2, and 4 mM DTT) for 5 min. The reaction was started by the addition of 5 mM ATP. Each assay condition was allowed to incubate at 37°C for 20 minutes before the addition of 100 μL of 5% SDS. To determine the release of inorganic phosphate, 500 μL of deionized water, 400 μL of Pi reagent (composed of 1% ammonium molybdate in 2.5 M sulfuric acid and 0.014% potassium antimonyl tartrate trihydrate) and 200 μL of 1% ascorbic acid was added to each tube. Color was allowed to develop for 10 minutes before the absorbance was measured spectrophotometrically at 880 nm. Absorbance values were used to calculate the rate of ATPase specific activity (nmoles P_i/min/mg protein).

**Flow cytometry P-gp transport function assay**

Cells were trypsinized, counted, and 2 × 10^5 cells per assay conditions were transferred into polystyrene flow cytometry tubes. Cells were incubated in IMDM containing 0.5 μM Rhodamine 123 (Rh123) with or without 100 nM of the P-gp inhibitor tariquidar at 37°C for 45 minutes. After incubation, cells were centrifuged, supernatant was removed, and cells were resuspended in 200 μL of cold PBS and placed on ice to stop transporter activity. A total of 10,000 individual cell-counting events were recorded using a FACS Canto II flow cytometer. A 488 nM blue laser was used to excite all fluorophores and emission was measured at 530 nm. FACS data were analyzed using FlowJo Single Cell Analysis software.

**Sigma 70 binding site analysis**

Promoters and ribosome binding sites were identified using sequence walkers as previously described [27,28].

**Statistical analysis**

Curve-fitting and all statistical analysis was performed using GraphPad Prism 6.0. Multiple groups were analyzed using one-way analysis of variance (ANOVA) where significance was defined as p < 0.05.

**Results**

**Characterization of mdr1a cDNA genetic instability in bacteria**

Plasmids containing mdr1a cDNA were constructed by PCR amplification of mouse mdr1a cDNA and ligation into the pCR-Blunt-II-TOPO vector using Zero Blunt TOPO PCR Cloning. Twenty clones were selected for plasmid purification and analysis by gel electrophoresis. Typically, 5% of all Zero Blunt TOPO PCR Cloning reactions result in the self-ligation of the vector without the PCR product of interest. However, when purified plasmids were analyzed for size by gel electrophoresis, only four of 16 plasmids displayed the ligation of mdr1a cDNA into the pCR-Blunt-II-TOPO vector. Each of the four potential mdr1a-containing plasmids were
sequenced (Fig 1). Three plasmids contained mdr1a cDNA with frameshift mutations (insertion or deletion mutations that would generate an out-of-frame protein if expressed). One contained a single point mutation that introduced a stop codon into mdr1a cDNA. These data indicate the presence of wild-type mdr1a cDNA in bacteria is intolerable, allowing only bacteria containing plasmids with mutated mdr1a cDNA to survive transformation.

To investigate whether mutations to mdr1a cDNA were specific to the Zero Blunt TOPO PCR Cloning system, mdr1a cDNA was ligated into an alternative vector for transformation into E. coli. The pCR-Blunt-II-TOPO vector containing mdr1a cDNA was used to transform E. coli and 20 colonies were selected for small-scale bacterial growth, plasmid purification, and analysis of plasmid DNA by agarose gel electrophoresis. Sixteen of the colonies selected for analysis contained large insertion or deletion mutations (not shown), and the remaining four colonies containing potentially correct mdr1a cDNA were sequenced. Each of the four sequenced plasmids contained mutated mdr1a cDNA, indicating a 100% mutational rate. Mutations observed were classified as point, insertion, or deletion mutations. Wild-type mdr1a cDNA (top) is compared to sequenced, “mutant” mdr1a cDNA (bottom). Insertion and point mutations are indicated in red in the mutant cDNA. Deleted base pairs are highlighted in red in wild-type cDNA, and the resulting mutated cDNA sequence is shown below. A) A point mutation (C→T) at location 1027 bp resulting in an introduced stop codon into mdr1a cDNA. B) A single adenine base pair insertion at location 1033 bp. C) Two examples of deletion mutations. All mutations resulted either directly (point mutations) or indirectly (insertion or deletion mutations) in the introduction of a stop codon into mdr1a cDNA. Locations of the introduced stop codons are indicated.

doi:10.1371/journal.pone.0136396.g001
In silico identification of a cryptic promoter in mdr1a cDNA

To investigate the possible presence of a cryptic promoter in mdr1a cDNA, in silico sigma 70 binding site analysis using information theory was used to search for potential bacterial promoters [27]. Additionally, information theory can identify sequences capable of initiating translation by identifying sequences similar to the bacterial ribosome binding site (RBS), which consists of both the Shine-Dalgarno sequence and the initiation codon [28,30,31]. By the identification of predicted transcriptional and translational initiation sites, potential open reading frames (ORF) can be detected.

The sigma 70 binding site analysis identified a sequence in mdr1a cDNA capable of acting as a bacterial promoter (Fig 2A and S1 Fig). This sequence consists of a classic extended -10 element (TGnTATAAT) located between 168–176 bps of mdr1a cDNA. The analysis did not predict the presence of a -35 element capable of promoter activity. However, previous studies have shown that the presence of an extended -10 element is capable of high levels of protein expression, even in the absence of additional promoter elements (-35 element/UP element) [32]. Thus, it is likely that the extended -10 element is responsible for transcription of mdr1a cDNA.

While this promoter is theoretically capable of initiating transcription, to support the hypothesis that mdr1a toxicity is due to the expression of P-gp, a RBS and translation start site must also be present in the cDNA. The analysis identified a RBS ideally spaced upstream of a methionine start (ATG) codon (Fig 2B). Additionally, the methionine is in-frame with regard to the ORF of mdr1a cDNA. In other words, if translation were initiated at this location, P-gp would be expressed in E. coli initiating at amino acid 107 and terminating at the native stop codon after amino acid 1276. Additionally, MDR1 human P-gp cDNA (MDR1 is 83% identical to mdr1a cDNA) was also analyzed by sigma 70 binding site analysis for the presence of a cryptic promoter, as this laboratory has not observed genetic instability of MDR1 cDNA. It did not predict that the corresponding MDR1 sequence would act as a bacterial promoter due to differences in the analogous sequence of the predicted -10 element, a fact that may explain why genetic instability is observed with mouse, but not human, P-gp cDNA (data not shown).

Sequences of mdr1a cDNA are able to drive GFP expression

To investigate the cryptic promoter predicted by the sigma 70 binding site analysis, a series of plasmids were generated containing truncations of mdr1a cDNA fused to GFP (Fig 3).
Plasmids were designed to investigate several aspects of the ability of \textit{mdr1a} cDNA to initiate transcription and translation in bacteria. As the \textit{in silico} analysis predicted a bacterial promoter between 168 and 176 bp, plasmid p300-GFP was generated to determine the ability of sequences in the first 300 bps of \textit{mdr1a} cDNA to promote GFP expression. Note that this construct contains an introduced RBS and ATG initiation codon to initiate GFP translation, and is therefore only reporting on the ability of the first 300 bps of \textit{mdr1a} cDNA to function as a bacterial promoter. In addition to a cryptic promoter that would initiate transcription, translation must also occur for the expression of mouse P-gp. The GFP fusion p321-GFP was generated to investigate the ability of \textit{mdr1a} to express GFP. Plasmid p321-GFP is composed of \textit{mdr1a} cDNA 1–321 bp, which includes the predicted cryptic promoter (\textit{mdr1a} bases 168–176), RBS (\textit{mdr1a} bases 309–314), and the mouse P-gp methionine at amino acid 107 (\textit{mdr1a} bases 319–321) fused in-frame with GFP lacking a start codon. GFP expression observed from this construct after transformation into bacteria would suggest that both the transcriptional and translational sequences identified by the \textit{in silico} analysis are functional.

Additionally, p321-M107L-GFP was constructed to encode a leucine rather than a methionine at position 107 in the amino acid sequence. This was generated in an attempt to abrogate GFP expression by removing the translational start site, and investigate if construction of the mutated form of \textit{mdr1a} harboring an M107L mutation would be desirable. Plasmid p-GFP, containing a stuffer region in lieu of a promoter, and \(\lambda\)pR-GFP, containing the strong \(\lambda\)pR promoter, were generated as controls.

The p300-GFP, p321-GFP, p321-M107L-GFP, \(\lambda\)pR-GFP, and p-GFP plasmids were used to transform \textit{E. coli}. Confocal microscopy was used to qualitatively determine levels of GFP expression in bacteria transformed with the p300-GFP, p321-GFP, p321-M107L-GFP, \(\lambda\)pR-GFP, and p-GFP plasmids (Fig 4A). Bacteria transformed with the p300-GFP and p321-GFP plasmids exhibited GFP expression. Confocal images of transformed bacteria were in qualitative agreement with fluorescence levels observed by fluorescence spectroscopy used to quantify the amount of GFP expression in transformed bacteria (Fig 4B). Bacteria transformed with the p300-GFP plasmid displayed significantly higher GFP expression as compared...
to p-GFP as seen by the increase in fluorescence intensity from 218 ± 61 RFU (p-GFP) to 12,255 ± 1,005 RFU (p300-GFP) (p ≤ 0.0001), indicating that the mdr1a cDNA sequence from 1–300 bp contains promoter elements able to initiate GFP transcription. The p321-GFP plasmid was used to determine if sequences 1–321 bp of mdr1a were able to express GFP by both the production of a transcript and subsequent translation into a protein product. Fluorescence intensity of the bacteria transformed with p321-GFP (4,110 ± 515 RFU) was also significantly higher than p-GFP (p ≤ 0.0001). However, p321-GFP was also significantly lower than observed with p300-GFP (p ≤ 0.0001). This is most likely due to the fact that the p300-GFP plasmid contains an introduced strong RBS with ideal positioning relative to the transcriptional start site. In contrast, the p321-GFP is predicted by the sigma 70 binding site analysis to contain a weaker RBS with less ideal spacing between the RBS and the transcriptional start site. Confocal images and fluorescence spectroscopy values for bacteria transformed with λpR-GFP plasmids were omitted due to the signal saturation resulting from high GFP fluorescence.

GFP fusion plasmid p321-M107L-GFP containing the M107L mutation had significantly lower GFP expression (1,636 ± 129 RFU) than bacteria transformed with the p300-GFP (12,255 ± 1,005 RFU) and p321-GFP (4,110 ± 515 RFU) plasmids (p ≤ 0.0001), indicating that introduction of the M107L mutation to full-length mdr1a may reduce toxicity and generate a more stable mdr1a cDNA. However, the M107L mutation did not completely abrogate GFP expression, as GFP levels in bacteria transformed with p321-M107L-GFP (1,636 ± 129 RFU) contained higher GFP expression than bacteria transformed with the negative control p-GFP (218 ± 61 RFU) plasmid DNA (p ≤ 0.01). Various explanations could account for GFP expression by the p321-M107L-GFP plasmid, such as the presence of another codon that may be able to initiate translation. For example, while ATG is the most common start codon, used to initiate translation in approximately 83% of genes in E. coli, GTG and TTG initiate translation in 14% and 3% of genes, respectively [33]. Additionally, translation of at least one gene in E. coli

Fig 4. Fluorescence of E. coli transformed with GFP fusion plasmids. (A) Confocal images of E. coli transformed with GFP fusion plasmids. From left to right, columns represent fluorescence, bright field, and a merged image. Yellow bars indicate 20 μm. (B) Fluorescence of E. coli transformed with GFP fusion plasmids. Fluorescence spectroscopy was used to determine levels of GFP fluorescence in bacteria transformed with GFP plasmids. Confocal images and fluorescence spectroscopy values for bacteria transformed with λpR-GFP plasmids were omitted due to the signal saturation resulting from high GFP fluorescence. Data represent the mean and standard deviation of five individual colonies from one transformation event. Multiple groups were analyzed using one-way ANOVA where significance was defined as p < 0.05 in GraphPad Prism.

doi:10.1371/journal.pone.0136396.g004
uses CTG (the codon used to generate the leucine mutation) as a start codon for translation [34].

**mdr1a M107L cDNA shows increased genetic stability during cloning**

While *mdr1a*-GFP fusion plasmids containing the M107L mutation had significantly less GFP expression, the critical question was whether the M107L mutation would reduce *mdr1a* cDNA-associated toxicity. Full-length *mdr1a* cDNA was mutated to introduce the M107L mutation to generate *mdr1a-M107L* cDNA. The *mdr1a-M107L* cDNA was ligated into a pDest-008 plasmid to generate the pDEST-*mdr1a-M107L* plasmid, which was used to transform *E. coli*. Three colonies were selected for small-scale culturing and subsequent plasmid purification and sequencing. All three pDEST-*mdr1a-M107L* purified plasmids contained non-mutated cDNA (apart from the introduced M107L mutation). Elimination of the translational start site associated with the cryptic bacterial promoter appeared to reduce the toxicity of *mdr1a* cDNA to bacteria.

**Functional characterization of M107L P-gp**

To evaluate if a mutation at residue 107 in *mdr1a* would be likely to affect protein function, the residue was located in the mouse P-gp crystal structure (Fig 5). Residue 107 is located at the boundary of extracellular loop 1 (ECL1) and transmembrane helix 1 (TM1). In this model, residue 107 does not face the drug-binding pocket, and would not be expected to influence function. Leucine was chosen as a replacement residue for methionine, as both are residues with hydrophobic side chains that are relatively similar in size, and the codon for leucine (CTG) is not expected to efficiently initiate translation.

To show that M107L P-gp was functionally similar to wild-type P-gp, complete functional characterization was initiated. Characterization of M107L P-gp was carried out in comparison to human P-gp. A more accurate assessment of M107L function would be to compare the functional activity of M107L P-gp to wild-type mouse P-gp, as species differences may occur.

---

**Fig 5.** Mouse P-gp model in apo (open) conformation with methionine residue at position 107 highlighted. (A) Mouse P-gp is shown with the methionine to leucine mutation highlighted in TM1-ECL1 by the presence of a space filled leucine residue. The region of the drug-binding pocket (DBP) is indicated. (B) Enlarged view of M107L mutation. Figures were generated using PyMOL from PDB deposit 4M1M [18].

doi:10.1371/journal.pone.0136396.g005
naturally between mouse and human P-gp, and these variables may confound functional differences resulting from the M107L mutation. However, due to mutations in wild-type mdr1a cDNA acquired during cloning, the plasmids required to carry out functional assays could not be generated. Therefore, all functional assays carried out used human P-gp as a control for M107L P-gp expression and function.

Vectors containing human P-gp cDNA and mouse P-gp cDNA with the M107L mutation (M107L P-gp) were used to transiently transfect HEK-293 cells for western blotting and flow cytometry studies. Western blotting was performed to determine if M107L P-gp was expressed at a level comparable to wild-type human P-gp. The C219 primary antibody was used for western blotting, as it recognizes an epitope conserved in all mammalian P-gps, including mouse and human P-gp [35]. HEK-293 cells transfected with human and M107L P-gp both expressed P-gp to equivalent levels (Fig 6A), whereas P-gp was not detected in untransfected HEK-293 cells.

Flow cytometry efflux assays were carried out to determine functionality of M107L P-gp compared to human P-gp. Rhodamine 123 (Rh123) is a fluorescent compound that is a substrate of mouse and human P-gp. HEK-293 cells transfected with human and M107L P-gp should efflux equivalent amounts of Rh123. Non-transfected HEK-293 cells should accumulate high intracellular levels of Rh123, as these cells lack P-gp-mediated efflux. The extent of P-gp-mediated efflux can be observed by the co-incubation of transfected cells with both Rh123 and the P-gp inhibitor tariquidar (TQR). HEK-293 cells transfected with human and M107L mouse P-gp effluxed Rh123 to a similar extent, as indicated by the low level of cellular fluorescence (Fig 6B). Non-transfected HEK-293 cells, which do not express P-gp, accumulated high levels of Rh123. Additionally, when cells transfected with human or M107L P-gp were co-incubated with Rh123 and TQR, P-gp-mediated efflux was abrogated, allowing Rh123 to accumulate in cells, as observed by the increased intracellular fluorescence to non-transfected levels. Thus, M107L P-gp was shown to be expressed and functional at a level similar to that of wild-type human P-gp.

ATPase activity is required for the transport of substrates by P-gp. Therefore, ATPase assays were carried out to determine biochemical differences in the ATP binding and hydrolysis between human and M107L P-gp. Various concentrations of verapamil were tested to measure ATPase activity of human and M107L P-gp (Fig 6C). Interestingly, M107L P-gp exhibited higher maximal fold stimulation than human P-gp. As the M107L mutation is not located in the drug-binding pocket and therefore not predicted to influence drug transport (Fig 5), this result may reflect a species difference between mouse and human P-gp. To determine if differences in ATPase activity were observed with additional compounds, a panel of seven compounds known to stimulate P-gp ATPase activity was screened (Fig 6D). The compounds cis-flupentixol, calcein AM (CAM), nicardipine, paclitaxel, vincristine, Rh123, and loperamide were used to probe for activity of M107L P-gp compared to human P-gp. Human and M107L P-gp showed similar levels of ATPase stimulation, indicating that M107L P-gp is functional and its ATPase activity can be stimulated to levels similar to those of human P-gp with the exception of nicardipine and verapamil stimulation. Overall, while M107L P-gp displayed higher levels of ATPase activity with certain substrates, M107L P-gp functionality was deemed similar to that of wild-type P-gp.

Discussion

The heterologous expression of some eukaryotic membrane proteins in bacteria can exert toxic or lethal effects due to perturbation of the bacterial cell membrane by the insertion of transmembrane-spanning domains [21–23]. However, to our knowledge, plasmids containing
mdr1a cDNA did not contain a bacterial promoter upstream of mdr1a, and thus protein expression or subsequent toxicity was not expected to occur. This study identifies and characterizes a cryptic bacterial promoter intrinsic to mouse mdr1a cDNA capable of protein expression. The genetic instability of plasmids containing mdr1a cDNA had been previously observed by several laboratories [36,37], but no study has formally reported the detrimental effects of plasmids containing mdr1a cDNA upon transformation into E. coli or characterized the basis of such effects. The experiments described in this study have identified the presence of sequences intrinsic to mdr1a cDNA that are able to initiate transcription and translation and thus induce protein expression. Additionally, this study reports a mdr1a M107L mutant generated by a single point mutation that is more genetically stable during cloning and retains the functional characteristics of wild-type P-gp.

**Fig 6. Functional characterization of M107L P-gp.** (A) HEK-293 cells were transiently transfected with plasmids containing human and M107L P-gp for subsequent western blotting with the C219 primary antibody. Additionally, the drug-selected cell lines C3M and KB-8-5-11 over-expressing wild-type mouse and human P-gp, respectively, were included. GAPDH was used as a loading control. (B) Rh123 efflux assay of HEK-293 cells transfected with human and M107L P-gp. Histograms shown are representative of three independent studies. (C) ATPase assays were carried out using crude membranes generated from High-five insect cells infected with recombinant baculovirus expressing human and M107L P-gp. ATPase activity of human WT and M107L P-gp in the presence of 0, 1, 5, 10, 25, 50 and 100 μM of verapamil. (D) Seven known stimulators of ATPase activity were selected to determine their effect on the activity of M107L P-gp compared to human WT P-gp. The following concentrations were used of each compound: 20 μM cis-flupentixol, 10 μM CAM, 20 μM nicardipine, 20 μM paclitaxel, 20 μM vincristine, 500 μM Rhodamine 123, and 20 μM loperamide. All ATPase data represent average and standard deviation of technical duplicates from three individual assays.

doi:10.1371/journal.pone.0136396.g006
The toxicity of foreign DNA in bacteria and the mechanism by which this occurs has been studied and often found to be due to cryptic promoters. This is a form of the 'pervasive transcription' reported to occur in the bacterial genome. While bacteria do have machinery to suppress pervasive transcription (binding by histone-like nucleoid protein, H-NS), this largely occurs against genes that are A/T-rich (mdr1a cDNA is unremarkable at 54% AT-rich) [38]. The ABC transporter CFTR (ABCC7) provides a notable example of the cryptic promoter phenomenon [39]. A seminal paper by Gregory et al. characterized such a cryptic bacterial promoter in CFTR cDNA [19]. The authors observed that E. coli transformed with plasmids containing human CFTR cDNA often yielded plasmids with extensive rearrangements, indicating that transformed bacteria might be selecting against propagation of the full length CFTR cDNA. To investigate if any portion of the CFTR cDNA was being unintentionally expressed due to the presence of a cryptic bacterial promoter, plasmids containing segments of CFTR fused to chloramphenicol acetyltransferase (CAT), a gene that confers resistance to chloramphenicol, were generated. The authors reported a region of CFTR cDNA between 908 and 936 bp that was able to generate chloramphenicol-resistant E. coli clones due to the expression of CAT. To abrogate protein expression of CFTR cDNA in E. coli, a T936C silent mutation was introduced into the identified -10 promoter element, therefore generating a cDNA mutant capable of propagating in bacteria [40–43]. More recently, a cryptic bacterial promoter was characterized in the cDNA encoding the Dengue virus (DENV) 5' untranslated region (UTR) [20]. Li et al. described the high mutation rate of plasmids containing DENV 5'UTR cDNA and identified sequences of cDNA highly homologous to bacterial -35 and -10 promoter elements that were able to express a toxic protein product.

Several early papers used cloning as a method for the propagation and amplification of plasmids containing mdr1a [12,44,45]. Unfortunately, published literature often did not report the exact cloning conditions (bacterial host strain used, bacterial growth conditions, etc.) and it was not possible to repeat the cloning strategy employed. It may be that various factors that allowed for the cloning of mdr1a in those early reports are no longer applicable. For example, plasmids used in earlier studies are now often considered to be 'low-copy number vectors', with plasmids present in bacterial cells in lower numbers than current commercially available plasmid vectors optimized for high plasmid yield; and lower plasmid copies per cell would be expected to decrease the deleterious effects of a cryptic promoter if present in mdr1a. Also, at their time of publication, sequence analysis was not standard practice, and it is possible that the constructs described may have contained unidentified compensatory mutations. Nonetheless, the limited published literature on this subject does not describe or characterize difficulty in cloning mdr1a.

A series of papers by Bibi et al. report methods for the expression of mdr1b (also termed mdr1), which is 83% homologous to mdr1a, using E. coli [36,46,47]. This suggests that, even if mdr1a was expressed in the presence of a cryptic promoter, the protein product would not be harmful to bacteria [48]. However, close inspection of these papers reveals multiple insights that would suggest the converse is true. For example, the authors screened a variety of bacterial host strains to identify a strain that was able to withstand mdr1b expression [36]. Additionally, the authors noted that high-copy number plasmids were not suitable for the expression of mdr1b, stating that high copy vectors increase the toxic effects of mdr1b in bacteria [36]. The authors also noted the presence of two distinct colony morphologies after bacterial transformation with plasmids containing mdr1b: large colonies that contained mutated mdr1b and small, slow-growing colonies containing wild-type mdr1b. Taken together, these data suggest that while certain bacterial strains and growth conditions may allow for the expression of mdr1b, its expression does exert a toxic effect when expressed in bacteria. Lastly, the authors attempted the expression of mdr1a in E. coli with various host strains, but several rearrangements of mdr1a cDNA were observed and expression could not be obtained (E. Bibi personal communication, Weizmann Institute of Science).
Lastly, a paper by Evans et al. describes attempts made to express human P-gp in *E. coli* for structural investigations where P-gp expression was deliberately driven by lac operon induction [37]. Expression of full-length human P-gp could not be attained. However, low-level expression of a truncated form of P-gp was detectable, and expression of the truncated protein was associated with a 500- to 1000-fold drop in colony forming ability [37]. Taken together with the current study, these data indicate that *E. coli* is not able to withstand the expression of either human or mouse P-gp; however, expression of human P-gp only occurs through plasmid-driven induction, while the expression of mouse P-gp occurs unintentionally through the activity of a cryptic promoter.

A thorough understanding of functional differences between mouse and human P-gp is a crucial step towards both the translation of *in vivo* animal studies to the clinic and a comprehensive understanding of the recently reported mouse P-gp crystal structures. To date, a severe impediment to the functional characterization of mouse P-gp has been the inability to reliably clone plasmids containing *mdr1a* cDNA. We hope that this study provides a warning to researchers working with *mdr1a* concerning its propensity to mutate during cloning. Our discovery of a cryptic promoter present in *mdr1a* is a possible explanation for the observed genetic instability of the plasmid. We believe that the M107L *mdr1a* mutant characterized here, which is capable of replication in *E. coli* with a reduced mutational rate, may prove useful for laboratories wishing to study *mdr1a* in the future.

Supporting Information

S1 Fig. Putative sigma 70 promoter and ribosome binding sites in mouse *mdr1a* cDNA. The coordinate system begins at the first base of the *mdr1a* coding region. For the first two sequences, flexible individual information models for *E. coli* sigma70 (yellow, red rectangular petals) and extended -10 sigma70 (green) and ribosome binding sites (purple and blue) were scanned over the sequence and displayed using sequence walkers. The third sequence shows the effect of changing base 319 from an A to a C in M107L. This lowers the initiation codon from 6.3 bits to -5.5 bits, effectively removing the ribosome binding site.

(PDF)

Acknowledgments

We would like to thank Daniel Schu for his microbiology expertise. A special thanks to George Leiman for editorial assistance. This project was funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract number HHSN261200800001E and the by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

Author Contributions

Conceived and designed the experiments: KMP DE MDH DRG SCH. Performed the experiments: KMP JKM JPM LVP VEW TDS. Analyzed the data: KMP DE MDH. Contributed reagents/materials/analysis tools: SS DE IP. Wrote the paper: KMP DE MDH TDS SVA DRG MMG.

References

1. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468–7485. PMID: 14576852
2. Kannan P, John C, Zoghbi SS, Hallidin C, Gottesman MM, Innis RB, et al. (2009) Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86: 368–377. doi: 10.1038/clpt.2009.138 PMID: 19625998

3. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219–234. PMID: 16518375

4. Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36: 179–194. PMID: 10837715

5. Sharom FJ (2011) The P-glycoprotein multidrug transporter. Essays Biochem 50: 161–178. doi: 10.1042/bse0500161 PMID: 21967057

6. Lin JH, Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42: 59–98. PMID: 12489979

7. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48–58. PMID: 11902585

8. Ambudkar SV (1998) Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol 292: 504–514. PMID: 9711578

9. Kim IW, Booth-Genthe C, Ambudkar SV (2008) Relationship between drugs and functional activity of various mammalian P-glycoproteins (ABCB1). Mini Rev Med Chem 8: 193–200. PMID: 18336339

10. Kim IW, Booth-Genthe C, Ambudkar SV (2008) Relationship between drugs and functional activity of various mammalian P-glycoproteins (ABCB1). Mini Rev Med Chem 8: 193–200. PMID: 18336339

11. Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa S, Ebihara T, et al. (2006) Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm Res 23: 1460–1472. PMID: 16779700

12. Tang-Wai DF, Kajiji S, Dicapua F, de Graaf D, Roninson IB, Gros P (1995) Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 34: 32–39. PMID: 7819214

13. Xia CQ, Xiao G, Liu N, Pimprale S, Fox L, Patten CJ, et al. (2006) Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using ATPase activity assays. Mol Pharm 3: 78–86. PMID: 16686372

14. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718–1722. doi: 10.1126/science.1168750 PMID: 19329113

15. Jin MS, Oldham ML, Zhang Q, Chen J (2012) Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 490: 566–569. doi: 10.1038/nature11448 PMID: 23000902

16. Li J, Jaimes KF, Aller SG (2014) Refined structures of mouse P-glycoprotein. Protein Sci 23: 34–46. doi: 10.1002/pro.2387 PMID: 24155053

17. Schlegel S, Klepsch M, Gialama D, Wickstrom D, Slotboom DJ, de Gier JW (2010) Revolutionizing membrane protein overexpression in bacteria. Microbiotechnol 3: 403–411. doi: 10.1111/j.1751-7915.2009.00148.x PMID: 20760620

18. Ward AB, Schewczyk P, Grimard V, Lee CW, Martinez L, Doshi R, et al. (2013) Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc Natl Acad Sci U S A 110: 13386–13391. doi: 10.1073/pnas.1309275110 PMID: 23901103

19. Gregory RJ, Cheng SH, Rich DP, Marshall J, Paul S, Hehir K, et al. (1990) Expression and characterization of the cystic fibrosis transmembrane conductance regulator. Nature 347: 382–386. PMID: 1699127

20. Li D, Aaskov J, Lott WB (2011) Identification of a cryptic prokaryotic promoter within the cDNA encoding the 5' end of dengue virus RNA genome. PLoS One 6: e18197. doi: 10.1371/journal.pone.0018197 PMID: 21483867

21. Montigny C, Penin F, Lethias C, Falson P (2004) Overcoming the toxicity of membrane peptide expression in bacteria by upstream insertion of Asp-Pro sequence. Biochim Biophys Acta 1660: 53–65. PMID: 14757220
24. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11: 117–126. PMID: 3856953
25. Currier SJ, Ueda K, Willingham MC, Pastan I, Gottesman MM (1989) Deletion and insertion mutants of the multidrug transporter. J Biol Chem 264: 14376–14381. PMID: 2569468
26. Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM, et al. (1998) Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37: 5010–5019. PMID: 9538020
27. Shultzaberger RK, Chen Z, Lewis KA, Schneider TD (2007) Anatomy of Escherichia coli sigma70 promoters. Nucleic Acids Res 35: 771–788. PMID: 17189297
28. Shultzaberger RK, Bucheimer RE, Rudd KE, Schneider TD (2001) Anatomy of Escherichia coli ribosome binding sites. J Mol Biol 313: 215–228. PMID: 11601857
29. Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM, et al. (1998) Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37: 5010–5019. PMID: 9538020
30. Schneider TD, Stormo GD, Gold L, Ehrenfeucht A (1986) Information content of binding sites on nucleotide sequences. J Mol Biol 188: 415–431. PMID: 3525846
31. Shultzaberger RK, Bucheimer RE, Rudd KE, Schneider TD (2001) Anatomy of Escherichia coli ribosome binding sites. J Mol Biol 313: 215–228. PMID: 11601857
32. Bai J, Swartz DJ, Protasevich II, Brouillette CG, Harrell PM, Hildebrandt E, et al. (2011) A gene optimization strategy that enhances production of fully functional P-glycoprotein in Pichia pastoris. PLoS One 6: e22577. doi:10.1371/journal.pone.0022577 PMID: 21826197
33. Shultzaberger RK, Bucheimer RE, Rudd KE, Schneider TD (2001) Anatomy of Escherichia coli ribosome binding sites. J Mol Biol 313: 215–228. PMID: 11601857
34. Missiakas D, Georgopoulos C, Raina S (1993) The Escherichia coli heat shock gene htpY: mutational analysis, cloning, sequencing, and transcriptional regulation. J Bacteriol 175: 2613–2624. PMID: 8478327
35. van Der Elsen JM, Kuntz DA, Hoedemaeker FJ, Rose DR (1999) Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein. Proc Natl Acad Sci U S A 96: 13679–13684. PMID: 10570132
36. Bibi E, Edgar R, Beja O (1998) Functional expression of mdr and mdr-like cDNAs in Escherichia coli. Methods Enzymol 292: 370–382. PMID: 9711568
37. Evans GL, Ni B, Hrycyna CA, Chen D, Ambudkar SV, Pastan I, et al. (1995) Heterologous expression systems for P-glycoprotein: E. coli, yeast, and baculovirus. J Bioenerg Biomembr 27: 43–52. PMID: 8492999
38. Singh SS, Singh N, Bonocora RP, Fitzgerald DM, Wade JT, Grainger DC (2014) Widespread suppression of intragenic transcription initiation by H-NS. Genes Dev 28: 214–219. doi:10.1101/gad.234336.113 PMID: 24449106
39. Quinton PM (1999) Physiological basis of cystic fibrosis: a historical perspective. Physiol Rev 79: S3–S22. PMID: 9922374
40. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066–1073. PMID: 2475911
41. Boyd AC, Popp F, Michaelis U, Davidson H, Davidson-Smith H, Doherty A, et al. (1999) Insertion of natural intron 6a-6b into a human cDNA-derived gene therapy vector for cystic fibrosis improves plasmid stability and permits facile RNA/DNA discrimination. J Gene Med 1: 312–321. PMID: 10738548
42. Wei L, Vankeerberghen A, Jaspers M, Cassiman J, Nilius B, Cuppens H (2000) Suppressive interactions between mutations located in the two nucleotide binding domains of CFTR. FEBS Lett 473: 149–153. PMID: 1082063
43. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, et al. (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827–834. PMID: 1699669
44. Dhir R, Gros P (1992) Functional analysis of chimeric proteins constructed by exchanging homologous domains of two P-glycoproteins conferring distinct drug resistance profiles. Biochemistry 31: 6103–6110. PMID: 1352702
45. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P (1995) Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698–1705. PMID: 7560060
46. Beja O, Bibi E (1996) Functional expression of mouse Mdr1 in an outer membrane permeability mutant of Escherichia coli. Proc Natl Acad Sci U S A 93: 5969–5974. PMID: 8650203
47. Bibi E, Gros P, Kaback HR (1993) Functional expression of mouse mdr1 in Escherichia coli. Proc Natl Acad Sci U S A 90: 9209–9213. PMID: 8105473

48. Devault A, Gros P (1990) Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 10: 1652–1663. PMID: 1969610